Loading
Ovarian Function and Disorders / Pituitary Gland Disorders and Treatments · Journal article
World Journal of Pharmacy and Pharmaceutical Sciences · September 3, 2026
Early or partial results. Treat as a signal, not a conclusion.
This systematic review characterizes lean PCOS (20–30% of PCOS patients) as a distinct phenotype driven primarily by neuroendocrine abnormalities rather than obesity-related metabolic dysfunction, and notes that diagnostic delays range from 5 to 15 years. The review proposes a framework for targeted, phenotype-specific therapies but does not present trial results or evidence comparing specific interventions.
Systematic review. Patients with polycystic ovary syndrome, particularly those presenting with normal or low body mass index. Intervention: Targeted, phenotype-specific therapeutic interventions for lean PCOS.
Lean PCOS phenotype comprises 20–30% of PCOS patients, characterized by normal or low BMI Diagnostic delays in lean PCOS span 5 to 15 years, driven by clinical biases overlooking non-obese phenotypes Lean PCOS pathophysiology is driven by accelerated GnRH pulse frequency and increased pulsatile LH secretion, independent of weight-induced metabolic syndrome
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should recognize lean PCOS as a distinct neuroendocrine disorder separate from obesity-associated PCOS, which may reduce diagnostic delays. Standard contraceptive therapy may not be appropriate for this phenotype; the review suggests phenotype-specific interventions are needed, though specific therapeutic recommendations are not detailed in this abstract.
A systematic review of diagnostic delays and pathophysiology in lean PCOS that synthesizes clinical trials and mechanistic insights, but reports no primary trial data, effect sizes, or comparative outcomes to support clinical decision-making.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should recognize lean PCOS as a distinct neuroendocrine disorder separate from obesity-associated PCOS, which may reduce diagnostic delays. Standard contraceptive therapy may not be appropriate for this phenotype; the review suggests phenotype-specific interventions are needed, though specific therapeutic recommendations are not detailed in this abstract.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Polycystic Ovary Syndrome (PCOS)—recently redefined in global consensus statements as Polyendocrine Metabolic Ovarian Syndrome (PMOS)—is typically characterized in clinical literature by its strong association with obesity and insulin resistance. However, a significant subset of patients (20–30%) present with a normal or low body mass index (BMI), defining the "lean PCOS" phenotype. This cohort experiences extensive diagnostic delays, often spanning 5 to 15 years, due to clinical biases that overlook non-obese phenotypes and the diagnostic mimicry of pubertal maturation. Pathophysiologically, lean PCOS is distinctly driven by reproductive neuroendocrine aberrations, primarily a profound acceleration in gonadotropin-releasing hormone (GnRH) pulse frequency and a subsequent increase in pulsatile luteinizing hormone (LH) secretion, operating independently of weight-induced metabolic syndrome. Although insulin resistance exists in lean phenotypes, it remains predominantly tissue-specific or visceral rather than systemic. Standard therapies, such as non-targeted combined oral contraceptive pills (COCPs), frequently mask symptoms while exacerbating subclinical metabolic profiles or inducing hypothalamic-pituitary-ovarian axis suppression. This systematic review synthesizes recent clinical trials and mechanistic insights to delineate the neuroendocrine and metabolic pathways of lean PCOS, quantifies the drivers of clinical diagnostic delays, and provides an evidence-based framework for targeted, phenotype-specific therapeutic interventions.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.